Xencor Reports XmAb®7195 Top-line Interim Phase 1a Results Showing Rapid Reduction of Serum IgE in Healthy Volunteers - 90% of subjects had reduction of free IgE to below the limit of detection by the end of XmAb7195 infusion, including at lowest dose evaluated of 0.3 mg/kg -- Dose limiting toxicity of thrombocytopenia observed at 3.0 mg/kg -- Enrollment continues in Part 2 of trial for high IgE subjects -- Conference call today at 8:30 a.m. ET -

MONROVIA, Calif., Jan. 29, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases and cancer, today reported top-line interim results from a Phase 1a study for XmAb®7195. The data show rapid reduction of circulating free IgE levels to below the limit of detection in 90% of XmAb7195 treated subjects that had detectable free IgE pre-dose, including those at the lowest dose evaluated of 0.3 mg/kg. Total IgE levels were also reduced in a parallel fashion. A dose limiting toxicity of transient, asymptomatic thrombocytopenia was observed...